Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran.
Phytother Res. 2024 Aug;38(8):3973-3985. doi: 10.1002/ptr.8261. Epub 2024 Jun 7.
Continuing research is being conducted on novel preventive and therapeutic drugs for cardiovascular diseases (CVDs). Daidzein has shown potential beneficial effects regarding various CVDs and risk factors. However, data in this regard are inconsistent, and there is an urge to accumulate. Therefore, we reviewed the effects of daidzein and daidzin on CVDs. We conducted a search through Scopus, PubMed, Google Scholar, and Web of Science from inception up to October 2023 to find studies with the primary intention of assessing the impacts of daidzein and daidzin on cardiovascular disease in various in vitro, animal, and clinical settings. In vitro and animal studies showed that daidzein and daidzin are effective in terms of reducing inflammation, oxidative stress, hyperlipidemia, myocardial infarction, thromboembolism, hypertension, and aneurysms. However, clinical studies only confirmed a relatively small portion of the previous findings of the in vitro and animal investigations, including anti-hyperlipidemic effects. In conclusion, in vitro and animal studies have reported potential therapeutic effects for daidzein and daidzin regarding CVDs. However, most of the clinical studies were unable to exhibit the same results. Hence, further clinical studies are required to determine the outcomes of administering daidzein and its derivatives for an extended period and in various doses.
正在对心血管疾病 (CVDs) 的新型预防和治疗药物进行持续研究。大豆苷元在各种 CVDs 和风险因素方面显示出潜在的有益作用。然而，这方面的数据不一致，需要积累。因此，我们综述了大豆苷元和大豆苷的作用对 CVDs 的影响。我们通过 Scopus、PubMed、Google Scholar 和 Web of Science 进行了搜索，从开始到 2023 年 10 月，以找到主要评估大豆苷元和大豆苷在各种体外、动物和临床环境中对心血管疾病影响的研究。体外和动物研究表明，大豆苷元和大豆苷在减轻炎症、氧化应激、高脂血症、心肌梗死、血栓栓塞、高血压和动脉瘤方面有效。然而，临床研究仅证实了体外和动物研究之前发现的一小部分结果，包括抗高血脂作用。总之，体外和动物研究报告了大豆苷元和大豆苷对 CVDs 的潜在治疗作用。然而，大多数临床研究未能显示出相同的结果。因此，需要进一步的临床研究来确定在延长时间和不同剂量下给予大豆苷元和其衍生物的结果。
